ABT (Abbott) beat Q2 earnings and revenue estimates and raised its 2026 EPS guidance, signaling improved forward momentum. Growth was driven by Medical Devices and Cancer Diagnostics, partially offset by weakness in Nutrition. The guidance lift and segment mix improvement are likely to support positive price action for the stock.
ABT (Abbott) beat Q2 earnings and revenue estimates and raised its 2026 EPS guidance, signaling improved forward momentum. Growth was driven by Medical Devices and Cancer Diagnostics, partially offset by weakness in Nutrition. The guidance lift and segment mix improvement are likely to support positive price action for the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
